Publication | Open Access

Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer

Phase 1/2Extended EvaluationMedicineImmunologyColorectal CancerTherapeutic VaccineImmune Checkpoint InhibitorLate-stage Colorectal CancerImmunotherapyOncologyRadiation OncologyTumor Microenvironment